Informed by nature
and guided by science
Informed
by nature
and guided
by science
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Bringing together leaders in the business of medicine and science
Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Our News
Psyence Group Inc. Closes Second Tranche of Non-Brokered Private Placement for Remaining Proceeds
TORONTO, ONTARIO, July 7, 2025 – Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), is pleased to announce that it has successfully closed the second tranche (“Tranche 2”) of its previously announced non‑brokered private placement (the “Offering”), relying on the accredited investor exemption under section 2.3 of National Instrument 45-106 — Prospectus Exemptions.
Psyence Group Inc. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of the Offering will be used for general working capital purposes.
Psyence Group Inc. Announces Offering of up C$600,000 Non-Brokered Private Placement of Common Shares
Psyence Group Inc are pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder’s fees or commissions will be payable in connection with the Offering.
